State Street’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-1,377,399
| Closed | -$248M | – | 3798 |
|
|
2017
Q3 | $248M | Sell |
1,377,399
-347,168
| -20% | -$48.4M | 0.02% | 603 |
|
|
2017
Q2 | $179M | Buy |
1,724,567
+221,895
| +15% | +$18.1M | 0.02% | 682 |
|
|
2017
Q1 | $118M | Sell |
1,502,672
-464,541
| -24% | -$28.7M | 0.01% | 856 |
|
|
2016
Q4 | $88.2M | Buy |
1,967,213
+383,693
| +24% | +$18.8M | 0.01% | 969 |
|
|
2016
Q3 | $88.5M | Buy |
1,583,520
+152,391
| +11% | +$8.49M | 0.01% | 943 |
|
|
2016
Q2 | $71.6M | Buy |
1,431,129
+98,982
| +7% | +$4.86M | 0.01% | 1000 |
|
|
2016
Q1 | $61.2M | Buy |
1,332,147
+312,481
| +31% | +$15.1M | 0.01% | 1084 |
|
|
2015
Q4 | $62.8M | Buy |
1,019,666
+114,715
| +13% | +$8.07M | 0.01% | 1044 |
|
|
2015
Q3 | $50.4M | Buy |
904,951
+34,459
| +4% | +$2.17M | 0.01% | 1171 |
|
|
2015
Q2 | $53.1M | Buy |
870,492
+367,274
| +73% | +$21M | 0.01% | 1227 |
|
|
2015
Q1 | $29M | Buy |
503,218
+384,010
| +322% | +$25.7M | ﹤0.01% | 1578 |
|
|
2014
Q4 | $6.87M | Buy |
119,208
+47,108
| +65% | +$1.98M | ﹤0.01% | 2402 |
|
|
2014
Q3 | $2.06M | Buy |
+72,100
| New | +$1.78M | ﹤0.01% | 2999 |
|
State Street's KITE Position: Q4 2017 in Review
State Street sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 1,377,399 shares — an estimated $248M sold.
State Street first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $248M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- State Street reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- State Street sold 1,377,399 Kite Pharma, Inc. shares in Q4 2017, an estimated $248M.
- State Street first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
- State Street's Kite Pharma, Inc. position peaked at $248M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on State Street's 13F filing for Q4 2017, filed 14 Feb 2018.